Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06248814
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-01-31
Brief Title:
A Study to Evaluate the Safety Tolerability Drug Levels and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase 1b Randomized Double-blind Placebo-controlled Single Dose Crossover Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of BMS-986326 at Two Dose Levels in Adult Participants With Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability drug levels drug effects and impact on disease severity of BMS-986326 in participants with moderate-to-severe atopic dermatitis AD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-502997-18 | REGISTRY | EU Trial Number | None |